Table 2: Changes in angiogenic factors and cytokines on VEGFR TKIs.
For each patient, plasma was collected at baseline and then either week 4 or week 6 on treatment. A repeated measures model was used to estimate baseline and followup values for each cytokine, and to test for differences between baseline and post-treatment time points.
| Molecule | Arm | Post-tx time point |
Baseline Log (pg/mL) | 95% CI | Follow-up | 95% CI | Bonferroni adjusted p |
|---|---|---|---|---|---|---|---|
| VEGF | Sunitinib | Week 4 | −2.22 | (−2.38, −2.07) | −1.56 | (−1.72, −1.41) | < 0.001 |
| Week 6 | −2.12 | (−2.31, −1.93) | −2.12 | (−2.31, −1.93) | 1 | ||
| Sorafenib | Week 4 | −2 | (−2.15, −1.84) | −1.74 | (−1.90, −1.59) | < 0.001 | |
| Week 6 | −2.22 | (−2.41, −2.04) | −1.94 | (−2.13, −1.76) | < 0.001 | ||
| Placebo | Week 4 | −2.18 | (−2.33, −2.03) | −2.24 | (−2.38, −2.09) | 1 | |
| Week 6 | −2.19 | (−2.37, −2.00) | −2.26 | (−2.44, −2.07) | 1 | ||
| PlGF | Sunitinib | Week 4 | −4.86 | (−5.00, −4.72) | −3.54 | (−3.69, −3.40) | < 0.001 |
| Week 6 | −4.77 | (−4.90, −4.65) | −4.63 | (−4.76, −4.51) | 0.013 | ||
| Sorafenib | Week 4 | −4.73 | (−4.87, −4.59) | −4.17 | (−4.31, −4.03) | < 0.001 | |
| Week 6 | −4.88 | (−5.01, −4.76) | −4.39 | (−4.52, −4.26) | < 0.001 | ||
| Placebo | Week 4 | −4.74 | (−4.88, −4.60) | −4.81 | (−4.95, −4.67) | 1 | |
| Week 6 | −4.87 | (−5.00, −4.75) | −4.96 | (−5.09, −4.83) | 1 | ||
| sFlt1 | Sunitinib | Week 4 | −2.59 | (−2.74, −2.44) | −2.75 | (−2.90, −2.60) | < 0.001 |
| Week 6 | −2.49 | (−2.65, −2.33) | −2.57 | (−2.73, −2.41) | 0.095 | ||
| Sorafenib | Week 4 | −2.53 | (−2.68, −2.38) | −2.6 | (−2.76, −2.45) | 0.66 | |
| Week 6 | −2.53 | (−2.69, −2.37) | −2.71 | (−2.87, −2.55) | < 0.001 | ||
| Placebo | Week 4 | −2.6 | (−2.75, −2.45) | −2.53 | (−2.68, −2.38) | 0.41 | |
| Week 6 | −2.52 | (−2.69, −2.36) | −2.59 | (−2.75, −2.43) | 0.47 | ||
| sVEGFR-2 | Sunitinib | Week 4 | 10.56 | (10.49, 10.64) | 10.06 | (9.98, 10.13) | < 0.001 |
| Week 6 | 10.61 | (10.51, 10.70) | 10.35 | (10.26, 10.44) | < 0.001 | ||
| Sorafenib | Week 4 | 10.61 | (10.54, 10.68) | 10.29 | (10.21, 10.36) | < 0.001 | |
| Week 6 | 10.6 | (10.50, 10.69) | 10.35 | (10.26, 10.45) | < 0.001 | ||
| Placebo | Week 4 | 10.64 | (10.56, 10.71) | 10.62 | (10.55, 10.70) | 1 | |
| Week 6 | 10.59 | (10.50, 10.68) | 10.57 | (10.47, 10.66) | 1 | ||
| Ang2 | Sunitinib | Week 4 | 8.4 | (8.20, 8.61) | 8.2 | (8.00, 8.41) | 0.29 |
| Week 6 | 8.51 | (8.32, 8.71) | 8.42 | (8.23, 8.61) | 1 | ||
| Sorafenib | Week 4 | 8.43 | (8.22, 8.63) | 8.46 | (8.26, 8.67) | 1 | |
| Week 6 | 8.38 | (8.19, 8.57) | 8.33 | (8.14, 8.52) | 1 | ||
| Placebo | Week 4 | 8.34 | (8.14, 8.54) | 8.38 | (8.19, 8.58) | 1 | |
| Week 6 | 8.5 | (8.31, 8.68) | 8.39 | (8.20, 8.58) | 0.65 | ||
| bFGF | Sunitinib | Week 4 | −4.89 | (−5.07, −4.71) | −4.89 | (−5.07, −4.71) | 1 |
| Week 6 | −4.91 | (−5.15, −4.67) | −4.61 | (−4.86, −4.37) | < 0.001 | ||
| Sorafenib | Week 4 | −4.87 | (−5.05, −4.69) | −4.86 | (−5.04, −4.68) | 1 | |
| Week 6 | −5.06 | (−5.30, −4.82) | −4.84 | (−5.08, −4.60) | 0.042 | ||
| Placebo | Week 4 | −5.11 | (−5.29, −4.93) | −5.08 | (−5.26, −4.91) | 1 | |
| Week 6 | −5.03 | (−5.27, −4.79) | −5.09 | (−5.33, −4.85) | 1 | ||
| HGF | Sunitinib | Week 4 | 5.28 | (5.14, 5.42) | 5.3 | (5.15, 5.44) | 1 |
| Week 6 | 5.25 | (5.10, 5.39) | 5.29 | (5.15, 5.44) | 1 | ||
| Sorafenib | Week 4 | 5.42 | (5.28, 5.56) | 5.31 | (5.18, 5.45) | 0.036 | |
| Week 6 | 5.23 | (5.08, 5.37) | 5.16 | (5.02, 5.31) | 1 | ||
| Placebo | Week 4 | 5.3 | (5.17, 5.44) | 5.31 | (5.18, 5.45) | 1 | |
| Week 6 | 5.31 | (5.16, 5.45) | 5.3 | (5.15, 5.44) | 1 | ||
| IFNγ | Sunitinib | Week 4 | 0.11 | (−0.35, 0.57) | 0.23 | (−0.22, 0.69) | 1 |
| Week 6 | −0.15 | (−0.52, 0.21) | 0.11 | (−0.25, 0.46) | 1 | ||
| Sorafenib | Week 4 | 0.2 | (−0.24, 0.63) | 0.2 | (−0.25, 0.66) | 1 | |
| Week 6 | −0.06 | (−0.42, 0.30) | −0.05 | (−0.41, 0.31) | 1 | ||
| Placebo | Week 4 | 0.04 | (−0.41, 0.49) | 0 | (−0.43, 0.44) | 1 | |
| Week 6 | 0.02 | (−0.34, 0.37) | −0.12 | (−0.48, 0.23) | 1 | ||
| IL8 | Sunitinib | Week 4 | 4.45 | (3.86, 5.05) | 4.82 | (4.24, 5.40) | 1 |
| Week 6 | 4.14 | (3.65, 4.64) | 4.01 | (3.51, 4.51) | 1 | ||
| Sorafenib | Week 4 | 4.7 | (4.13, 5.27) | 4.77 | (4.19, 5.35) | 1 | |
| Week 6 | 4.48 | (3.99, 4.97) | 4.06 | (3.57, 4.55) | 0.55 | ||
| Placebo | Week 4 | 3.88 | (3.30, 4.46) | 4.35 | (3.78, 4.91) | 0.92 | |
| Week 6 | 4.46 | (3.98, 4.95) | 4.09 | (3.60, 4.57) | 1 | ||
| CXCL9 | Sunitinib | Week 4 | 3.91 | (3.71, 4.11) | 4.84 | (4.64, 5.04) | < 0.001 |
| Week 6 | 4.19 | (3.99, 4.39) | 4.23 | (4.03, 4.42) | 1 | ||
| Sorafenib | Week 4 | 4.04 | (3.86, 4.22) | 4.37 | (4.18, 4.55) | < 0.001 | |
| Week 6 | 4.11 | (3.92, 4.31) | 4.23 | (4.03, 4.42) | 0.28 | ||
| Placebo | Week 4 | 4.04 | (3.85, 4.22) | 4 | (3.82, 4.19) | 1 | |
| Week 6 | 3.98 | (3.79, 4.17) | 3.93 | (3.74, 4.12) | 1 | ||
| CXCL10 | Sunitinib | Week 4 | 4.18 | (3.98, 4.38) | 5.19 | (4.99, 5.39) | < 0.001 |
| Week 6 | 4.39 | (4.19, 4.59) | 4.61 | (4.42, 4.81) | < 0.001 | ||
| Sorafenib | Week 4 | 4.33 | (4.14, 4.52) | 4.89 | (4.70, 5.09) | < 0.001 | |
| Week 6 | 4.37 | (4.17, 4.56) | 4.58 | (4.39, 4.77) | < 0.001 | ||
| Placebo | Week 4 | 4.33 | (4.14, 4.52) | 4.5 | (4.31, 4.68) | 0.33 | |
| Week 6 | 4.28 | (4.09, 4.47) | 4.28 | (4.09, 4.47) | 1 | ||
| CXCL11 | Sunitinib | Week 4 | 5.49 | (5.31, 5.67) | 5.77 | (5.59, 5.95) | < 0.001 |
| Week 6 | 5.4 | (5.21, 5.59) | 5.5 | (5.31, 5.69) | 0.76 | ||
| Sorafenib | Week 4 | 5.5 | (5.32, 5.67) | 5.68 | (5.51, 5.86) | 0.002 | |
| Week 6 | 5.42 | (5.24, 5.61) | 5.46 | (5.27, 5.64) | 1 | ||
| Placebo | Week 4 | 5.37 | (5.19, 5.54) | 5.42 | (5.25, 5.59) | 1 | |
| Week 6 | 5.39 | (5.21, 5.57) | 5.44 | (5.25, 5.62) | 1 |